FDA Approves Novo Nordisk’s Rybelsus For Cardiovascular Risk Reduction In Type 2 Diabetes Patients Finances October 18, 2025 (RTTNews) – Novo Nordisk introduced that the US Meals and Drug Administration has permitted Rybelsus—the one oral GLP-1 remedy—for decreasing…
